LONDON (ShareCast) - (Sharecast News) - Neuroscience technologies firm Ixico announced on Monday that it has furthered its relationship with a top 10 pharmaceutical company through a new £1m contract.
The AIM traded company will provide its imaging services in a study of people with early manifest Huntington's disease to observe the natural progression of the disease, with Ixico's TrialTracker technology being used to standardise the collection of MRI scans.

The firm will also apply proprietary image analysis algorithms to measure neurological changes in study participants.

Giulio Cerroni, chief executive of IXICO, said: "Today's announcement continues IXICO's successful track record in providing neuroimaging clinical trial services for Huntington's disease, representing our third new contract in this therapeutic area in the current financial year. I am delighted that we continue to win new business with existing clients which I believe demonstrates the value placed by our customers on the unique combination of technologies and scientific expertise that we provide."

Huntington's is a rare neurodegenerative disease that affects movement, cognition and behaviour, that has no effective marketed treatments.

Ixico first became involved in the study of the disease in 2007, supporting early observational studies led by academic centres in Europe and North America, and has since been providing its services to clinical trials concerning the condition.

As of 1041 BST, Ixico's shares were down 3.71% at 30.33p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE